Abstract: An acrylic sealant is configured to seal a graphite disk that comprises: (a) one or more of a di- or tri-functional acrylate monomers, a mono-functional [meth]acrylate monomer, and an oligomeric monomer including a plurality of [meth] acrylate functional groups; and (b) a radical initiator. A method for making an impregnated, cured disk includes the steps of (a) positioning a raw graphite disk into a vacuum/pressure chamber; (b) applying a vacuum in the chamber after the raw graphite disk is positioned there; (c) immersing the raw graphite disk in a liquid acrylic sealant in the chamber after the vacuum is applied; (d) removing the vacuum in the chamber and applying a pressure to sufficiently impregnate the raw graphite disk with the liquid acrylic sealant and create an impregnated graphite disk; (e) placing the impregnated graphite disk into a curing chamber; and (f) in the curing chamber, heating the impregnated graphite disk in order to cure the liquid acrylic sealant inside of the graphite disk.

Abstract: A zero calibration method includes: adding, based on a first forward kinematics model of a robotic arm of a robot, zero deviations of each joint to form a second forward kinematics model, and simultaneously solving the second forward kinematics model and the first forward kinematics model to obtain an end deviation function; sending target end pose instructions to the robotic arm in a current zero point situation, and acquiring a spatial deviation of an actual position of an end; inputting position information of each joint angle and the spatial deviation, after each stop of motion of the end, into the end deviation function, and performing phase shifting to obtain an objective optimization function; and solving the objective optimization function to obtain a zero deviation value.

Abstract: Provided are a recombinant adeno-associated virus (rAAV) genome and a single-polarity rAAV (spAAV) vector formed by packaging same. Specifically, provided is an spAAV genome before packaging, two ends of which are both linear open terminuses, wherein one end does not have an inverted terminal repeat (ITR) or a part thereof, and the other end has a truncated ITR (ITRT), and the ITRT does not form a T-shaped hairpin palindromic structure. The spAAV genome is a single-polarity single-stranded DNA. Also provided are an spAAV vector, a method for delivering an exogenous nucleic acid to a cell by using the vector, and a use of the vector in the preparation of a product for gene expression, gene therapy, gene editing or gene regulation.

Abstract: A lattice-based proxy signature method, apparatus and device, a lattice-based proxy signature verification method, apparatus and device, and a storage medium. Polynomials are randomly selected in rings to calculate public and private keys of nodes, and the magnitudes of proxy public and private keys are the same as the magnitudes of public and private keys of an original signer. Therefore, compared with existing proxy signature schemes, the present application has smaller lengths of public and private keys and higher storage efficiency. Proxy signature information generated in the present application shows a signature of the original signer and also shows a signature of a proxy signer. Once a proxy signature is created, the proxy signature cannot be repudiated by the proxy signer, and has strong non-repudiation and strong unforgeability. The proxy signature method has the advantage of resisting quantum computer attack.

Abstract: The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins.

Abstract: A new mutant of D-amino acid transaminase, based on supercomputing-assisted technology, belongs to the fields of computational biology, computer-aided design, and enzyme engineering technology, and specifically relates to mutants of D-amino acid transaminase obtained based on supercomputing-assisted technology and applications thereof. Compared to the wild-type enzyme, the aforementioned mutant of D-amino acid transaminase exhibits a half-life (t1/2) of over 12 hours at 40° C., while it is only 8.8 minutes for the wild-type D-amino acid transaminase. The half-inactivation temperature (T5015) of the mutant is 45.3° C., approximately 5.4° C. higher than that of the wild-type D-amino acid transaminase. This substantially enhances its thermal stability, enzymatic activity, etc., effectively broadening its application fields and scope. The mutant has a wide range of industrial applications and thus holds substantial practical value.

Abstract: The present disclosure is directed synthetic methods for the preparation of 4-valyloxybutyric acid. The synthetic methods described herein employ a diverse array of protecting group strategies and reaction conditions. Additionally, the present disclosure is directed to compounds useful as synthetic intermediates in the preparation of 4-valyloxybutyric acid.

Abstract: A sealant for use in vacuum pressure impregnation, wherein the sealant includes at least one monomer that is at least partially hydrophilic, at least one monomer that is at least partially hydrophobic, and wherein the sealant has a density less than the density of water.

Abstract: A method for forging a niobium-tungsten alloy forged ring, including: (S1) subjecting an alloy ingot to turning, chamfering, spraying with an anti-oxidation coating, stainless-steel sheathing, heating and upsetting to obtain a primary pancake with a flat-die hammer, rapid-forging press or hydraulic press; (S2) subjecting an inner pole to wire electrical discharge machining to obtain a ring blank followed by machining to remove the stainless-steel sheath and oxide scale and defects; and subjecting the ring blank to fluorescent/dye penetrant inspection followed by vacuum stress-relief annealing; (S3) subjecting the ring blank to core shaft/saddle forging on the flat-die hammer or rapid-forging press to obtain a crude forged ring; and (S4) subjecting the crude forged ring to vacuum recrystallization annealing to obtain a desired forged ring.

Abstract: The present disclosure provides a truncated Evans Blue modified fibroblast activation protein inhibitor compound. The compound is formed by connecting truncated Evans Blue, a fibroblast activation protein inhibitor and a nuclide chelating group by means of connecting groups L1, L2, L3, L4 and X. The compound has the following structure shown in Formula (I), where R1 is a fibroblast activation protein inhibitor; L1 is lysine, glutamic acid, or a derivative structure thereof; L2 is —(CH2)n—, n is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O—, —NH—, —(CO)—, —NH(CO)—, or —(CO)—NH—; L3 is —(CH2)m—, m is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O— or —(CO)—; L4 is —(CH2)p—, p is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O—, —NH—, —(CO)—, —NH(CO)—, or —(CO)—NH—; X is selected from N, C, O, S, or and R2 is a nuclide chelating group.

Abstract: A new mutant of D-amino acid transaminase, based on supercomputing-assisted technology, belongs to the fields of computational biology, computer-aided design, and enzyme engineering technology, and specifically relates to mutants of D-amino acid transaminase obtained based on supercomputing-assisted technology and applications thereof. Compared to the wild-type enzyme, the aforementioned mutant of D-amino acid transaminase exhibits a half-life (t1/2) of over 12 hours at 40° C., while it is only 8.8 minutes for the wild-type D-amino acid transaminase. The half-inactivation temperature (T505) of the mutant is 45.3° C., approximately 5.4° C. higher than that of the wild-type D-amino acid transaminase. This substantially enhances its thermal stability, enzymatic activity, etc., effectively broadening its application fields and scope. The mutant has a wide range of industrial applications and thus holds substantial practical value.

Abstract: The present disclosure is directed synthetic methods for the preparation of 4-valyloxybutyric acid. The synthetic methods described herein employ a diverse array of protecting group strategies and reaction conditions. Additionally, the present disclosure is directed to compounds useful as synthetic intermediates in the preparation of 4-valyloxybutyric acid.

Abstract: The present disclosure relates to the fields of nuclear medicine and molecular imaging, and specifically relates to a dual-targeting compound and a preparation method and application thereof. The dual-targeting compound has the following structure shown in Formula (I). The present disclosure also provides a dual-targeting compound capable of being labeled with a radionuclide, and the compound has the following structure shown in Formula (I-1) or Formula (1-2). The dual-targeting compound of the present disclosure has high affinity for an FAP target and an integrin ?v?3 target, can realize synergistic targeting of the FAP target and the integrin ?v?3 target in tumors, and has high uptake in tumors and long retention time in tumors.

Abstract: The present disclosure provides a truncated Evans Blue modified fibroblast activation protein inhibitor compound. The compound is formed by connecting truncated Evans Blue, a fibroblast activation protein inhibitor and a nuclide chelating group by means of connecting groups L1, L2, L3, L4 and X. The compound has the following structure shown in Formula (I), where R1 is a fibroblast activation protein inhibitor; L1 is lysine, glutamic acid, or a derivative structure thereof; L2 is —(CH2)n—, n is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O—, —NH—, —(CO)—, —NH(CO)—, or —(CO)—NH—; L3 is —(CH2)m—, m is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O— or —(CO)—; L4 is —(CH2)p—, p is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O—, —NH—, —(CO)—, —NH(CO)—, or —(CO)—NH—; X is selected from N, C, O, S, or and R2 is a nuclide chelating group.

Abstract: The present disclosure relates to the fields of nuclear medicine and molecular imaging, and specifically relates to a dual-targeting compound and a preparation method and application thereof. The dual-targeting compound has the following structure shown in Formula (I). The present disclosure also provides a dual-targeting compound capable of being labeled with a radionuclide, and the compound has the following structure shown in Formula (I-1) or Formula (I-2). The dual-targeting compound of the present disclosure has high affinity for an FAP target and an integrin ?v?3 target, can realize synergistic targeting of the FAP target and the integrin ?v?3 target in tumors, and has high uptake in tumors and long retention time in tumors.

Abstract: The present disclosure is related to systems and methods for medical imaging. The method includes determining a sequence of scan states of a medical device for a sequence of regions of interest (ROIs) of a subject. Each of the sequence of scan states corresponds to an ROI in the sequence of ROIs. When the medical device is in a scan state of the sequence of scan states, an isocenter of the medical device is aligned with a center of the corresponding ROI. The method includes generating a set of controlling information of the medical device based on the sequence of scan states. Each of the set of controlling information is configured to switch the medical device to a corresponding scan state in the sequence of scan states. The method includes controlling the medical device to scan the sequence of ROIs. Before scanning each of the sequence of ROIs, the medical device is positioned to the corresponding scan state according to the corresponding controlling information.

Abstract: A sealant configured to saturate and seal a graphite plate, such as a type of graphite plate that may be used in a hydrogen (H2) fuel cell, wherein the sealant may be one or more, or a mixture, of ethoxylated monomers. In some embodiments herein the sealant does not have an acid or a surfactant. Also disclosed is a graphite sheet impregnated with a sealant.

Abstract: The three-stage axial flow degassing device adopts an efficient degassing technology including a vertical high speed swirling field, a horizontal rapid axial flow field and a vertical reversing scrubbing field formed by a combination of vertical tubes; the first-stage degasser performs the first-stage segmental vertical high speed swirling degassing operation, removes the gas phase carried by the gas-containing fluid, and forms a primary gas and a primary fluid; the microporous uniform mixer breaks bubbles of the primary fluid and forms a gas-liquid uniform mixed flow; the second-stage degasser performs the second-stage horizontal vane wheel swirling generating rapid axial flow degassing operation, removes the gas phase carried by the gas-liquid uniform mixed flow, and forms a secondary gas and a secondary fluid; the third-stage degasser performs the third-stage vertical reversing deep degassing operation, removes liquid phase carried by the secondary gas, and forms a tertiary gas and a tertiary fluid.